ATE126806T1 - Neues kristallisationsverfahren von steroidverbindungen und so produzierte verbindungen. - Google Patents

Neues kristallisationsverfahren von steroidverbindungen und so produzierte verbindungen.

Info

Publication number
ATE126806T1
ATE126806T1 AT92900237T AT92900237T ATE126806T1 AT E126806 T1 ATE126806 T1 AT E126806T1 AT 92900237 T AT92900237 T AT 92900237T AT 92900237 T AT92900237 T AT 92900237T AT E126806 T1 ATE126806 T1 AT E126806T1
Authority
AT
Austria
Prior art keywords
pct
compounds
mixture
produced
date
Prior art date
Application number
AT92900237T
Other languages
English (en)
Inventor
Michel Lanquetin
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Application granted granted Critical
Publication of ATE126806T1 publication Critical patent/ATE126806T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT92900237T 1990-11-12 1991-11-12 Neues kristallisationsverfahren von steroidverbindungen und so produzierte verbindungen. ATE126806T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013981A FR2668945B1 (fr) 1990-11-12 1990-11-12 Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.

Publications (1)

Publication Number Publication Date
ATE126806T1 true ATE126806T1 (de) 1995-09-15

Family

ID=9402062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900237T ATE126806T1 (de) 1990-11-12 1991-11-12 Neues kristallisationsverfahren von steroidverbindungen und so produzierte verbindungen.

Country Status (17)

Country Link
US (1) US5266712A (de)
EP (1) EP0510167B1 (de)
JP (1) JP3281954B2 (de)
KR (1) KR100196895B1 (de)
AT (1) ATE126806T1 (de)
BR (1) BR9106012A (de)
CA (1) CA2073760C (de)
DE (1) DE69112379T2 (de)
DK (1) DK0510167T3 (de)
ES (1) ES2079172T3 (de)
FI (1) FI111545B (de)
FR (1) FR2668945B1 (de)
GR (1) GR3018117T3 (de)
HU (1) HU212780B (de)
LV (1) LV11183B (de)
RU (1) RU2126013C1 (de)
WO (1) WO1992008730A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
DK1361881T3 (da) * 2000-12-14 2006-02-20 Ortho Mcneil Pharm Inc Steroide hormonprodukter og fremgangsmåder til fremstilling heraf
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
EP1727520A2 (de) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Verfahren zur herstellung von mischphasen-kokristallen mit wirkstoffen
WO2005074942A1 (en) * 2004-02-04 2005-08-18 Retmed Pty Ltd Slow release steroid composition
RU2253453C1 (ru) * 2004-03-15 2005-06-10 Общество с ограниченной ответственностью "ЮНАЛ" Противовоспалительная и антиаллергическая композиция
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
EP1931682A2 (de) * 2006-08-03 2008-06-18 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von clopidogrel-bisulphat
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
MX393195B (es) * 2012-06-18 2025-03-24 Therapeuticsmd Inc Capsula de estradiol soluble para insercion por via vaginal
CN112871079B (zh) * 2021-01-27 2023-05-16 丽江映华生物药业有限公司 醋酸诺美孕酮微粒的制备方法及制备装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) * 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2361847A (en) * 1937-09-04 1944-10-31 Schering Corp Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3
US2897216A (en) * 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3836628A (en) 1972-05-22 1974-09-17 Int Research & Dev Co Ltd Crystal growth modifier
DE2323812A1 (de) * 1973-05-11 1974-11-28 Jenapharm Veb Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe
GB1515284A (en) * 1974-05-21 1978-06-21 Gastaud J Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
US4634694A (en) * 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4795747A (en) * 1985-12-23 1989-01-03 Latman Neal S 16-epiestriol to prevent, inhibit or reduce inflammation
US4956600A (en) * 1988-07-01 1990-09-11 Viteq Corporation High frequency current detector for a low frequency line

Also Published As

Publication number Publication date
JP3281954B2 (ja) 2002-05-13
HU212780B (en) 1996-11-28
DE69112379D1 (de) 1995-09-28
GR3018117T3 (en) 1996-02-29
RU2126013C1 (ru) 1999-02-10
EP0510167A1 (de) 1992-10-28
FR2668945A1 (fr) 1992-05-15
US5266712A (en) 1993-11-30
LV11183B (en) 1996-10-20
KR927003617A (ko) 1992-12-18
DK0510167T3 (da) 1996-01-02
CA2073760C (fr) 2003-09-23
JPH05503305A (ja) 1993-06-03
ES2079172T3 (es) 1996-01-01
KR100196895B1 (ko) 1999-06-15
HUT61319A (en) 1992-12-28
BR9106012A (pt) 1993-01-05
FR2668945B1 (fr) 1993-02-19
DE69112379T2 (de) 1996-03-28
LV11183A (lv) 1996-04-20
HU9202608D0 (en) 1992-10-28
FI923188L (fi) 1992-07-10
CA2073760A1 (fr) 1992-05-13
FI111545B (fi) 2003-08-15
EP0510167B1 (de) 1995-08-23
WO1992008730A1 (fr) 1992-05-29
FI923188A0 (fi) 1992-07-10

Similar Documents

Publication Publication Date Title
DE69112379D1 (de) Neues kristallisationsverfahren von steroidverbindungen und so produzierte verbindungen.
RU2001118035A (ru) Этанолят азитромицина, процесс получения и содержащие его фармацевтические составы
DE69330963D1 (de) Herstellung von aluminosilikatzeolithen
DK162518B (da) Fremgangsmaade til fremstilling af en stabil modifikation af torasemid, samt et farmaceutisk praeparat indeholdende denne
KR900013950A (ko) (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 화합물 및 약학적 담체를 함유한 약학적 조성물
JPS6471816A (en) Pharmacologically useful polymetamorphosis of buspirone
IT1165252B (it) Procedimento di purificazione dell'acido ursodesossicolico attraverso nuovi derivati
NO165195C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nye derivater av 4,5-dihydro-oksazolyl-2-((2-pyridyl)-metyl-tio- eller metylsulfinyl)-benz- eller tienoimidazoler.
TR18478A (tr) Yueksek safiyet derecesinde paraksilen' in kurtarilmasi icin tek safhah kristallestirme usulue
CO4480032A1 (es) Cristales de glicosidos de espiroestanilo
Suzuki Duration of development capacity of egg after ovulation in the loach, cyprinid fish
US2915431A (en) 2-(2'-isopropyl-4'-chloro-5'-methyl)-phenoxymethyl-2-imidazoline and its pharmaceutical uses
Yershov et al. Preparation of gallium arsenide films on insulators by artificial epitaxy
EP0939068A4 (de)
US2557655A (en) Estrone-cyclo-ethanolamine
SU1737036A1 (ru) Способ извлечени монокристаллов YB @ С @ О @ из затвердевшего раствора-расплава
JPS5373507A (en) Crystallization of pentaerythritol
JPS55140792A (en) Manufacture of 3-5 group compound semiconductor single crystal
JPS51114064A (en) Liquid phase growth and concerned unit
STROITELEV Crystallographic and chemical aspects of semiconductor technology(Russian book)
JPS61109770A (ja) ２位置にα‐ヒドロキシル鎖が置換した４‐ヒドロキシ‐３‐キノリンカルボン酸より誘導される新エステル、その製造、薬剤としての使用及びそれを含む組成物
JPS549257A (en) Preparation of highly pure 1,8-dihydroanthraquinone
CA2132417A1 (en) A crystalline modification of 2,4-dioxo-6-methyl-1, 2,3,4-tetrahydropyrimidine, a method for the preparation thereof and a medical preparation based on it
JPS51111477A (en) Method of preparation of semiconductor crystals
JPS51136582A (en) Process for production of a semi -conductor crystal

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time